Effect of treating psoriasis on cardiovascular Co-morbidities: Focus on TNF inhibitors

American Journal of Clinical Dermatology

Volumn 15, Issue 1, 2014, Pages 45-50

  Famenini, Shannon ^a   Sako, Eric Y ^a   Wu, Jashin J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYCLOSPORIN; ETANERCEPT; METHOTREXATE; RETINOID; TUMOR NECROSIS FACTOR INHIBITOR;

CARDIOVASCULAR DISEASE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; REVIEW; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INSULIN RESISTANCE; PSORIASIS; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893272086     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0052-6     Document Type: Review

References (46)

1. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899- 912.
2. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-6.
3. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273(2):197-204.
4. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577-83.
5. Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Investig Dermatol. 2013;133(10):2347-54.
6. Wakkee M, Meijer W, Neumann HA, et al. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol. 2009;89(5):476-83.
7. Gu WJ, Weng CL, Zhao YT, et al. Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2013;168(5):4992-6.
8. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14(4):343-8.
9. Pieringer H, Pichler M, Pohanka E, et al. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis? Curr Pharm Des. 2013 [Epub ahead of print].
10. Bili A, Tang X, Pranesh S, et al. TNF-α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 [Epub ahead of print].
11. Solomon DH, Curtis JR, Saag KG, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med. 2013;126(8):730.
12. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576-82.
13. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1213-8.
14. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediat Inflamm. 2012;2012:674265.
15. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066-73.
16. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Investig Dermatol. 2010;130(4):962-7.
17. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262-7.
18. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244-50.
19. Wu JJ. Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA. 2013;310(10):1075-6.
20. Wu JJ, Poon KY. Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. J Am Acad Dermatol. 2013;69(1):167-8.
21. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273(2):197-204.
22. Lestre S, Diamantino F, Veloso L, et al. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol. 2011;21(6):916-20.
23. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175-9.
24. Ferretti G, Bacchetti T, Campanati A, et al. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012;166(1):204-7.
25. Bacchetti T, Campanati A, Ferretti G, et al. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol. 2013;168(5):984-9.
26. Asefi M, Vaisi-Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167(6):1279-86.
27. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49-57.
28. Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis. 2009;68(6):868-72.
29. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30.
30. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25(10):1187-93.
31. Soeki T, Tamura Y, Shinohara H, et al. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93:168-74.
32. Gutierrez M, De Angelis R, Bernardini ML, et al. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept. Br J Dermatol. 2011;164(1):33-7.
33. Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141.
34. Coto-Segura P, Eiris-Salvado N, González-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783-93.
35. Mazlin MB, Chang CC, Baba R. Comorbidities associated with psoriasis - data from the Malaysian psoriasis registry. Med J Malays. 2012;67(5):518-21.
36. Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes mellitus: a Danish nationwide cohort study. Diabetes Care. 2013;36(8):2402-7.
37. Cerman AA, Bozkrut S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159:820-6.
38. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-31.
39. Martínez-Abundis E, Reynoso-von Drateln C, Hernández- Salazar E, et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299(9):461-5.
40. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731-6.
41. Cheung D, Bryer-Ash M. Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2009;60(6):1032-6.
42. Wambier CG, Foss-Freitas MC, Paschoal RS, et al. Severe hypoglycemia after initiation of antitumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009;60(5):883-5.
43. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol. 2008;144(10):1403-4.
44. Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-α for rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):178-9.
45. Maddahi A, Kruse LS, Chen QW, et al. The role of tumor necrosis factor-α and TNF-α receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflamm. 2011;8:107.
46. CieÅlak M, Wojtczak A, CieÅlak M. Relationship between the induction of inflammatory processes and infectious diseases in patients with ischemic stroke. Acta Biochim Pol. 2013;60(3):345-9.